US court permits early launch of generic version of Teva MS drug

July 26, 2013 20:55

WASHINGTON - Teva Pharmaceutical Industries' multiple sclerosis drug Copaxone will lose its patent protection in 2014 rather than 2015 because of a ruling from a US appeals court Friday.

The US Court of Appeals for the Federal Circuit issued its decision in a patent fight between Teva and rivals Sandoz and Mylan Inc.The result is that a generic version of Copaxone can be launched in May 2014, a year early.

Related Content

Breaking news
August 19, 2019
U.S. records 21 measles cases in a week, worst outbreak since 1992


Cookie Settings